Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing

被引：0
|
作者：
Taihang Shao
Mingye Zhao
Leyi Liang
Wenxi Tang
机构：
[1] China Pharmaceutical University,Center for Pharmacoeconomics and Outcomes Research
[2] China Pharmaceutical University,Department of Public Affairs Management, School of International Pharmaceutical Business
来源：
BioDrugs | 2023年 / 37卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：421 / 432
页数：11
相关论文
共 50 条
  • [1] Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing
    Shao, Taihang
    Zhao, Mingye
    Liang, Leyi
    Tang, Wenxi
    BIODRUGS, 2023, 37 (03) : 421 - 432
  • [2] Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing
    Gan, Yena
    Shi, Fenghao
    Zhu, He
    Han, Sheng
    Li, Duoduo
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Qin, Qun
    Zhu, Hong
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [4] Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first line treatment of extensive-stage small-cell lung cancer
    Zhou, Kexun
    Zhou, Jing
    Huang, Jiaxing
    Zhang, Nan
    Bai, Liangliang
    Yang, Yu
    Li, Qiu
    LUNG CANCER, 2019, 130 : 1 - 4
  • [5] Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
    Kang, Shuo
    Liu, Huanlong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (09) : 1081 - 1088
  • [6] Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China
    Long, Yunchun
    Xu, Yuan
    Liao, Li
    Zhou, Yujie
    Wang, Hao
    BMJ OPEN, 2023, 13 (08):
  • [7] Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer
    You, Maojin
    Luo, Lingling
    Lu, Tingting
    Chen, Shaofang
    He, Ying
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [8] Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer
    Zheng, Zhiwei
    Chen, Hongcai
    Cai, Hongfu
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [9] Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Li, Yan
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [10] Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
    Liu, Qiao
    Tan, Chongqing
    Yi, Lidan
    Wan, Xiaomin
    Peng, Liubao
    Li, Jianhe
    Luo, Xia
    Zeng, Xiaohui
    PLOS ONE, 2021, 16 (11):
12345